What species does this antibody react with, and has it been used in relevant studies?
The Anti-EAAT2 antibody is reactive with mouse and rat species. It has been utilized in various studies, including those investigating the role of astrocytic glutamate transporters in neurodegenerative conditions and the effects of glial cell activation on neuronal excitability (beaudet2015, fullana2019, sompol2017).
Can this antibody be effectively used for immunocytochemistry, and are there any specific protocols mentioned in the literature?
Yes, the Anti-EAAT2 antibody has been shown to work in immunocytochemistry applications. For instance, it was used at a dilution of 1:100 in a study examining the expression of glutamate transporters in astrocytes (fullana2019, iacobucc2021).
Has this antibody been cited in studies related to neurodegenerative diseases, and if so, what findings were reported?
The Anti-EAAT2 antibody has been cited in studies related to neurodegenerative diseases, such as amyotrophic lateral sclerosis and Alzheimer's disease. For example, it was used to assess the expression of glutamate transporters in activated astrocytes, which are implicated in the pathophysiology of these conditions (rizor2021, sompol2017).
What is the significance of the target protein, EAAT2, in astrocyte function, and how has this antibody contributed to research in this area?
EAAT2 is crucial for the uptake of glutamate in the central nervous system, helping to prevent excitotoxicity. The Anti-EAAT2 antibody has facilitated research into how dysregulation of this transporter contributes to neurodegenerative diseases, as seen in studies that explore the impact of glial cell function on neuronal health (peng2019, silvaada2020).